Evidence map›Paper›PMID 33044045›Full record

ArticleThoracic cancer2020

Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.

Hiroyuki Minemura, Hiroshi Moriya, Hisao Imai, Tomohide Sugiyama, Yutaka Yamada, Mitsunori Higuchi, Kyoichi Kaira, Yuki Ozaki, Kenya Kanazawa, Hiroshi Yokouchi and 5 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Hiroyuki MinemuraDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.ORCID 0000-0001-8710-1960
Hiroshi MoriyaDiagnostic Imaging Center, Ohara General Hospital, Fukushima, Japan.
Hisao ImaiDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan.ORCID 0000-0003-3097-4255
Tomohide SugiyamaDivision of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Japan.
Yutaka YamadaDivision of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Mitsunori HiguchiDepartment of Thoracic Surgery, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan.
Kyoichi KairaDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan.ORCID 0000-0001-5548-7686
Yuki OzakiDepartment of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Kenya KanazawaDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Hiroshi YokouchiDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Takashi KasaiDivision of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Japan.
Takayuki KaburagiDivision of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Hiroyuki SuzukiDepartment of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Koichi MinatoDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan.
Yoko ShibataDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Fukushima Medical University · JPHyogo Prefectural Cancer Center · JPIbaraki Prefectural Central Hospital · JPTochigi Cancer Center · JPNational Hospital Organization Hokkaido Medical Center · JPSaitama Medical University · JPSeirei Hamamatsu General Hospital · JP

Funding

Boehringer Ingelheim
6 · The paper itself

Abstract

backgroundNivolumab is known to demonstrate superior overall survival compared with docetaxel in pretreated non-small cell lung cancer (NSCLC) patients. Programmed death-ligand 1 (PD-L1) expression is reported to predict the outcome of treatment by nivolumab in lung cancer patients. However, the significance of the morphological characteristics of chest computed tomography (CT) as predictors of nivolumab efficacy for advanced NSCLC patients remains unknown.

methodsWe performed a multicenter retrospective trial from April 2013 to March 2017, to assess the significance of CT morphological characteristics as predictors of nivolumab efficacy for advanced NSCLC patients. A total of 78 NSCLC patients pretreated with nivolumab were enrolled. A chest radiologist used chest CT to assess the following morphological characteristics of each patient's main tumor and intrathoracic status prior to nivolumab treatment; interstitial septal thickening, peritumoral ground-glass opacity, spiculated margin, air bronchogram, cavity or necrosis, adjacent organ invasion, bulky lymph node, and accumulation of small lymph nodes. Logistic regression and Cox proportional hazards regression models were used to analyze outcomes.

resultsA total of 60 (77%) patients were male and 72 (92%) had a performance status (PS) of 0 or 1. The objective response rates of male patients and heavy smokers were significantly higher than those of female patients and light or never smokers, respectively. Multivariate analysis identified light or never smoking, poor PS, histological type of squamous cell carcinoma, and interstitial septal thickening as independent negative predictors of progression free survival (PFS).

conclusionsInterstitial septal thickening was a significant and independent predictor of PFS in NSCLC patients treated with nivolumab. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Interstitial septal thickening is an independent predictor of progression free survival in non-small lung cancer patients treated with nivolumab. WHAT THIS STUDY ADDS: The current study reveals the significance of morphological characteristics obtained via chest computed tomography as a predictor of nivolumab efficacy for advanced non-small cell lung cancer patients.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedNivolumabPrognosisRetrospective StudiesSurvival AnalysisTomography, X-Ray ComputedAntineoplastic Agents, ImmunologicalNivolumabComputed tomographyinterstitial septal thickeningnivolumabnon-small cell lung cancerpredictive biomarker

Identifiers

PMID33044045
PMCPMC7705921
OpenAlexW3092059442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.